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apy. Methods: Observational, non-interventional, prospective, single-center study 
of 1 year follow-up from ITB implant onward. Results: 20 consecutive patients with 
ITB indication were recruited; 13 received an ITB implant during the study period; 
1 implant was rejected and thus explanted. 12 patients, of whom 10 had spasticity 
due to spinal-cord injury, 1 to multiple sclerosis and 1 to adrenoleukodistrophy, pro-
vided data for the study and 9 completed follow-up. After 12 months of ITB, mean 
changes from baseline were: -2.6 on the Penn scale (p= 0.011), -1.1 (p= 0.059) and -2.8 
(p= 0.011) on the Ashworth upper and lower scale, respectively and +4.4 on the FIM 
scale (p= 0.075). Mean utility gain, assessed with the HUI3 scale, was 0.054 (p= 0.091) 
after 1 year. Mean total ITB test and permanent implant cost per patient were € 528 
and € 14,225, respectively. Mean quarterly spending on oral antispastics decreased 
by € 42 at month 12, while consumption of intrathecal baclofen stabilized after 6 
months at € 39. At baseline, 4 patients received botulinum injections, while none 
did at the end of follow-up. Catheter-related adverse events occurred in 2 out of 12 
patients, with a total mean cost per event of € 2.387. While waiting to receive ITB, 
spasticity-related hospitalizations due to urological complications occurred in 2 out of 
20 patients, with a mean cost of € 9.044 per event; no such events were observed after 
ITB implant. ConClusions: Clinical outcomes of patients with N-FDS improved 
after ITB. Initial therapy costs were considerable, but were partially offset by savings 
in drugs and spasticity-related events after 1 year follow-up. Results should be inter-
preted cautiously because of the small number of observations.
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objeCtives: Pseudobulbar Affect (PBA) is a neurologic disorder of emotional 
expression, resulting in frequent and involuntary episodes of crying and/or laugh-
ing. Common neurological conditions associated with PBA include: Alzheimer’s 
disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, stroke 
and traumatic brain injury. Nuedexta® (Avanir Pharmaceuticals Inc.) is the only 
EMA-approved PBA treatment. The financial impact of introducing Nuedexta to 
a national health care system, including Scotland, has never been formally esti-
mated. Methods: An Excel® based cost-calculator was developed. Prevalence, 
epidemiology and mortality estimates for causative neurological conditions as 
well as PBA prevalence in those conditions were sourced from the literature. Unit 
costs (drugs, hospitalisation etc.) were taken from national databases and standard 
care treatment mix and resource use were derived from a US claims database. A 
range of market uptake rates were used with further sensitivity analyses under-
taken. Results: The estimated cost of standard care in Scotland for PBA is circa 
£32.4 million annually (circa 22,500 patients). In year 1 following introduction, 67 
patients are expected to receive Nuedexta, resulting in a cost increase by £0.1 mil-
lion to £32.5 million. By year five, 836 patients are estimated to receive Nuedexta, 
resulting in a projected total annual cost of £34.6 million. Therefore the estimated 
annual budget impact of Nuedexta ranges from £0.15 million (year 1) to £1.88 mil-
lion (year 5). The incremental cost per patient is £2,246. The model was sensitive 
to changes in uptake rates, cost of background therapy and PBA symptom severity. 
When patients with moderate to severe PBA symptoms receive treatment, the pro-
jected cumulative year 5 budget impact estimate is £7.56 million. ConClusions: 
The estimated financial impact of introducing Nuedexta in Scotland is modest. Even 
if more patients are identified, the relatively small incremental cost per-patient of 
Nuedexta is unlikely to have a major impact on the Scottish NHS.
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objeCtives: To analyze factors of recent evolution of Multiple Sclerosis (MS) Disease 
Modifying Therapies (DMT) budgets in Spain between 2004 and 2013. Methods: 
2004-2013 single DMT monthly expenditure was provided by IMS Health. Monthly and 
annually evolution of number of patients, billing, drug cost per patient and cost per 
year of treatment were calculated. Two periods: 2004-2013 and 2007 (start marketing 
second lines DMT) -2013 period were analyzed for each DMT line. (First line: subcutane-
ous and intramuscular interferon (IFN) β -1a, subcutaneous IFN β -1b and glatiramer acetate 
injection. Second line: natalizumab and fingolimod). Results: During 2004-2013 DMT 
expenditure increased from € 115.5M to € 319.3M due to: A greater number of patients 
147% (10.60 % annual growth per year) and a further growth of annual cost per patient: 
12% (1.29 % annual growth per year). In December 2013 second lines correspond to 
a 29.61% of DMT expenditure. Annual cost per patient in second line represents 70% 
over cost per treated patient and 83% greater than first line DMT cost per year. If 
year 2007 is omitted from analysis (Only 68 second-line treatments and M1.44€ of 
associated expense) and is analyzed 2008-2013 period, second-line DMT represent 
43% of new treatments causing a 60% increase in DMT expenditure. In 2013 second 
line DMT participation reaches 64% of new regimens causing the 79% of increase DMT 
expenditure. ConClusions: The growing incorporation of new therapies and the 
noticeable rise in the number of treated patients (10.60 % annual growth per year) are 
components to consider in the pharmaceutical budget management.
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objeCtives: Comprehensive economic costs of multiple sclerosis (MS) accord-
ing to EDSS states can only be assessed by evaluating MS management in real 
clinical practice. The objective of this cross-sectional study was to measure the 
association of Khorasan privence (the widest province in Iran ). Quality of life was 
measured with MSQOL-54 instrument. Data was collected by employing a 32- item 
self-administered questionnaire in a face to face interview. Parametric, nonpara-
metric tests and descriptive statistics analysis were applied (p value< 0.05). Patients 
were grouped into three disability stages according to their Expanded Disability 
Scale Score (EDSS). Results: The Patients mean age was 31.78 (SD: 9.67 ) years, 
% 73.8 were female and %26.3 were male, and their mean EDSS was 2.4 (SD; 1.26) 
whereas EDSS increases, the costs also increases, which is a positive correlation. 
The mean QOL was 0.54 that as QOL increases, the costs decreases, which is a nega-
tive correlation. The MS medications (Interferon) have a cost around $ 46625 per 
year for each patient that are subsidized about $ 24452 IR by governmental sector. 
Up to $ 17104 are paid by insurance and $ 5263 directly by patients. The costs per 
patient-year were calculated as $ 11560) - 27970.5591 (EDSS= 1-2.5), $ 29916.909- 
30015.645 (EDSS= 3-4.5) and $34678.776- 34793.22 (EDSS= 5- 7.5). ConClusions: 
We conclude that the costs are relevant in MS, especially when disability increases. 
The catastrophic cost has a high burden to patients, society and health care system
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objeCtives: The primary objective of this study is to elucidate the effect of whole 
exome sequencing (WES) in diagnosing children with a developmental delay due to 
unexplained conditions presumed to be genetic. A secondary objective is to collect 
all resources used by these children to gain insight into the total costs over time for 
the traditional diagnostic pathway and the additional costs to diagnose a patient 
using WES. Methods: We included twenty children at the Sylvia Toth Centre (STC) 
in Utrecht, the Netherlands, who have underwent previously extensive clinical diag-
nostic workups and for whom no diagnosis was found after the last extensive workup. 
On all twenty children and parents WES will be performed, thereby obtaining a list 
of exonic candidate mutations for each patient. In parallel all resources used were 
collected by assessing the clinical records of patients. These resources were linked 
to unit costs to obtain the total cost per patient. Total cost per patient was then com-
pared to the cost of care using WES, assessed for each individual patient. Results: 
The diagnostic yield from the 13 patients sequenced thus far is 23% indicating a 23% 
increase in number of diagnoses compared to the current diagnostic pathway. On 
average these patients have had numerous visits to the hospital, overnight stays 
and different diagnostic workups to unravel the genetic cause of their neurologi-
cal disorder. Total cost of the current diagnostic pathway is therefore up to ten fold 
higher compared to the total cost of only providing WES. ConClusions: Comparing 
the diagnosis and costs with and without the use of WES gives a clear picture of the 
clinical and economic feasibility of putting WES into standard diagnostic practice at 
the STC and similar genetic centers over the world.
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objeCtives: To estimate the clinical and financial impact of Interferon beta-1a 
intramuscular (IM) and subcutaneous (SC) formulations in Portugal, based on the 
findings from Cochrane review regarding first-line treatments for relapsing-remit-
ting multiple sclerosis. Methods: An Excel-based model estimated the number of 
relapses and costs incurred by a hypothetical cohort of 1000 patients treated with 
two types of interferon beta-1a. The model evaluated the consequences of treatment 
with SC versus IM interferon beta-1a, as this was the only comparison whose data 
quality was assessed as ‘high’ by the Cochrane Review (Filippini 2013). Risk of relapse 
was based on the 2-year data from the Cochrane meta-analysis. The analysis was 
performed from a Portuguese National Health Service (NHS) perspective including 
only direct costs. Although efficacy was kept constant as Cochrane did not report 
outcomes based on Expanded Disability Status Scale (EDSS), costs of relapse were 
available for patients with different EDSS values, thus allowing estimation of cost 
impact for different types of population. Results: According to the model, treat-
ment with IM interferon beta-1a is expected to result in a total of 743 episodes of 
relapse, whereas SC interferon beta-1a is expected to result in a total of 570 cases, 
less 173 cases, over a 2-year period. Use of the SC formulation in a population with 
EDSS ≤ 3 will result in savings of € 690,213.04 over the 2-year period due to avoided 
relapses. In a more severe population, with EDSS between 3.5 and 4.5, these savings 
are expected to be € 889,865.74 over the same 2-year period. ConClusions: When 
compared with the IM formulation, the use of SC interferon beta-1a seems to be 
associated with fewer cases of relapse, resulting over a 2-year period in considerable 
potential savings to the NHS in terms of relapses avoided.
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objeCtives: To assess clinical outcomes, health care resource utilization and asso-
ciated costs of intrathecal baclofen therapy (ITB) for the treatment of non-focal 
disabling spasticity (N-FDS) in patients who are resistant or intolerant to oral ther-
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A397
objeCtives: To use health economic modeling techniques to quantify and compare 
the clinical and economic outcomes associated with the use of subcutaneous inter-
feron beta-1a (scIFNβ 1a) vs. intramuscular interferon beta-1a (imIFNβ 1a) over 2 years 
in the management of relapsing forms of multiple sclerosis (MS) from a US health 
care payer perspective. Methods: The 2-year decision analytic model was popu-
lated with IMS LifeLink Plus prevalence and treatment data, and clinical data from 
the EVIDENCE (EVidence of Interferon Dose-response: European North American 
Comparative Efficacy) study, a direct head-to-head comparison of 44 mcg scIFNβ 1a 
three times a week vs. 30 mcg imIFNβ 1a once a week. Relapse data from 16-month 
results were extrapolated for the 2-year model. Disease-modifying drug (DMD) costs 
were based on 2014 wholesale average cost with consideration of patient copay-
ment in the base case. The model was created with the ability to customize the rate 
of copayment as well as to incorporate contractual discounts, if desired. One-way 
sensitivity analyses were conducted on key parameters using alternate plausible 
values, including the rates of real-world DMD adherence. Results: For a hypotheti-
cal health plan with 1 million members, it is estimated that 911 patients with MS 
would be treated with DMDs. More relapses were avoided with scIFNβ 1a over 2 years 
(979) than with imIFNβ 1a over 2 years (778). The average cost-effectiveness of 44 mcg 
scIFNβ 1a was lower (more favourable) than the average cost-effectiveness of 30 mcg 
imIFNβ 1a ($123,854 vs. $148,749 per relapse avoided). Sensitivity analyses around 
model input values showed the model was robust and cost-effectiveness results 
were consistent. The model results are most sensitive to drug cost. ConClusions: 
Cost-effectiveness assessment may facilitate the decision-making process in select-
ing MS treatments. Using the highest-quality clinical data (Level 1, head-to-head 
study, EVIDENCE), the cost-effectiveness of 44 mcg scIFNβ 1a was shown to be favour-
able compared with 30 mcg imIFNβ 1a.
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objeCtives: To evaluate the cost-effectiveness of 44 mcg subcutaneous interferon 
beta-1a (scIFNβ 1a) and intramuscular interferon beta-1a (imIFNβ 1a) during the com-
parative and open-label extension phases of the EVIDENCE (EVidence of Interferon 
Dose-response: European North American Comparative Efficacy) study. Methods: 
A decision analytic model from a US health care payer perspective was populated 
with 2-year data from the EVIDENCE study of imIFNβ 1a and 44 mcg scIFNβ 1a (com-
parative and open-label extension phases). EVIDENCE results showed that the annu-
alized relapse rate of 44 mcg scIFNβ 1a patients was 0.46 during the comparative 
phase and 0.34 during the open-label extension phase. The annualized relapse rate 
of imIFNβ 1a patients during the comparative phase was 0.64. imIFNβ 1a patients who 
switched to 44 mcg scIFNβ 1a for the open-label extension phase had an annualized 
relapse rate of 0.32. These data were used to model the cost-effectiveness of 44 mcg 
scIFNβ 1a and imIFNβ 1a patients during the comparative phase as well as for the 
combined comparative and open-label extension phases (for patients remaining 
on scIFNβ 1a throughout and for those switching from imIFNβ 1a in the comparative 
phase to scIFNβ 1a in the open-label extension). Disease-modifying drug (DMD) cost 
was based on 2014 wholesale average cost with consideration of patient copayment 
in the base case. Results: The cost-effectiveness for 44 mcg scIFNβ 1a and imIFNβ 1a 
during the comparative phase was $123,854 and $148,749 per relapse avoided, 
respectively. The cost-effectiveness of patients who remained on 44 mcg scIFNβ 1a 
throughout the study was $99,398 per relapse avoided, while the cost-effectiveness 
of imIFNβ 1a patients who switched to 44 mcg scIFNβ 1a for the open-label extension 
was $116,404 per relapse avoided. Sensitivity analyses showed that the model was 
robust and was most sensitive to DMD cost. ConClusions: This decision analytic 
model evaluation shows that remaining on 44 mcg scIFNβ 1a and switching from 
imIFNβ 1a to 44 mcg scIFNβ 1a were cost-effective treatment strategies.
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objeCtives: To assess the cost-effectiveness of Lacosamide (LCM) in the manage-
ment of epileptic partial onset seizures (POS) versus standard AED therapy in Greece, 
as well as its impact on the health care budget. Methods: A cost-effectiveness 
model was developed simulating the treatment pathway of a hypothetical cohort of 
1000 patients over two years. A comprehensive literature search was conducted to 
identify local resource use data for medical, pharmaceutical and hospital treatment. 
Due to lack of relevant data, an expert panel with 8 neurologists was convened. The 
perspective was that of the Social Insurance Fund, and unit costs were taken from 
officially published sources (Ministry of Health and Social Insurance Fund). Primary 
and secondary analyses were carried out, in which the treatment algorithm was 
based on trial data and was adapted to the Greek setting, respectively. Deterministic 
and probabilistic sensitivity analyses were conducted to test the model’ results. In 
addition, a budget impact analysis (BIA) was carried out to estimate the annual 
cost of treating uncontrolled epileptic patients in Greece. Results: Treatment with 
LCM was shown to be dominant compared to standard therapy, as it is associated 
with 38 additional QALYs and reduced cost by € 410,024 and € 754,684 in the primary 
resource utilisation and the costs associated with health care management of MS 
in Slovakia and to provide a basis for cost-effectiveness evaluations. Methods: 
Descriptive epidemiological data of 2,552 MS patients from 27 MS-centers across 
Slovakia were collected electronically and analyzed. In 152 selected patients fol-
lowed up in 2011-2012 in 34 MS centers, all types of health care services and costs 
were analyzed. These patients were randomly included in the study. Continuous 
variables were calculated using standard descriptive statistical methods. Results: 
77% of patients had the relapsing-remitting form of MS (RRMS); 60 % of patients 
were in EDSS 1-3, mean age of patients at the time of diagnosis was 32.3 (± 9.7) years, 
and 68% of patients were females. Total direct health care costs, DMT excluded, 
ranged from € 752 to EDSS 1 to € 2,839 to EDSS 7, being the lowest for EDSS9 (at 
€ 963). Costs for DMT ranged from € 8,584 for EDSS1 to € 13,026 in EDSS4, being lower 
for EDSS6 (€ 1,668) and none for EDSS7-9.67% patients were receiving 1st line DMT, 
and 14 % receiving 2nd line treatment. DMT was mostly applied in EDSS 2 (97%). 
The most frequently used DMTs were glatiramer acetate (20%), interferon beta-
1a IM (15%), natalizumab (9%) and fingolimod (5%). The most expensive grade 1/2 
adverse events were abdominal pain (46.62 € ), pain in joints, back and arms (39.35 € ). 
ConClusions: This cross-sectional study determined the average annual direct 
cost per MS patient to be € 1,640; DMT excluded. As the EDSS increases, DMT costs 
decrease (except of EDSS1-2) and the costs of medical devices rise.
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objeCtives: In Spain, Parkinson Disease Associations (PDA) offers a wide range of 
care services with partial and variable financial support from the government. The 
study objective was to estimate the costs of PDA services and to calculate the poten-
tial savings that they represent to the National Health System (NHS). Methods: 
A survey conducted by the Federation of PDA collected information on their loca-
tion, number of members, type and use by patients of the offered services. Services 
were classified according to whether or not they were financed by the NHS, based 
on the existing national portfolio for reimbursed services. Weekly use was recorded 
and costs were calculated upon official rates (updated to € , 2014). Potential savings 
for the NHS were estimated by calculating the weekly cost associated to unfinanced 
services that were provided by the PDA. Results: 42 Spanish PDA that embraced a 
total of 11,420 patients participated in the study. From the 26 services offered, speech 
therapy (n= 41), physiotherapy (n= 39), cognitive stimulation (n= 23) and occupa-
tional therapy (n= 23) were the most frequently offered and used. The weekly cost 
associated to the provided services was € 655,219.87 [mean: € 15,980.97 (SD: 22,662.98)] 
per PDA. 53.8% of services were classified as potentially refundable by the NHS. Costs 
assaignable to potentially financed services represented 78.29%, reaching savings for 
the NHS of € 512,971.60/week. The cost of physiotherapy (27.3%) and of the adapted 
transport (21.3%) were the main components. Costs attributable to services not usually 
financed by the NHS accounted for 21.71% (€ 142,248.23), mostly attributable to cognitive 
stimulation costs (63.39%). ConClusions: PDA offer valuable services to patients and 
carers and afford a major proportion of the costs of the supportive and complementary 
care of the disease. Their economic efforts imply great savings to the NHS in Spain.
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objeCtives: To compare clinical outcomes (reduction in relapse number) and 
costs associated with multiple sclerosis (MS) treatment with one of the interferon 
β in the Czech Republic in five-year horizon based on development of neutral-
izing antibodies (NAbs) and patient non-adherence. Intramuscular (IM) interferon 
β -1a is characterized by very high adherence rate and low rate of NAbs produc-
tion. Methods: Markov cohort model was developed with one-year cycle length. 
In the Czech Republic, patients with MS initiate treatment with one of the interferon 
β . NAbs-positive patients (in the model, NAbs are detected during the second year of 
treatment and thereafter) are switched/escalated to a different disease modifying 
drugs; DMD (glatiramer acetate, fingolimod, natalizumab). If patients experience 
two or more relapses during one year of treatment, they are escalated to fingoli-
mod or natalizumab. Adherence data, development of NAbs, relapse rate and costs 
were sourced from the literature. Results: One hundred patients, who initiated 
treatment with IM interferon β -1a, experienced 287 relapses over 5 years. Those, 
who started treatment with subcutaneous (SC) interferon β -1a and interferon β -1b, 
experienced by 15 and 19 relapses more. In one hundred patients, total cost of 
treatment with IM interferon β -1a was 6.4 million € . This was about 139-200 thou-
sand € less compared to SC interferon β -1a and interferon β -1b. Hence incremental 
cost-effectiveness ratio was -262 thousand € /relapse avoided and -285 thousand 
€ /relapse avoided. ConClusions: Intramuscular interferon β -1a represents domi-
nant intervention in MS treatment, i. e. cost-saving treatment from payer’s perspec-
tive and simultaneously more efficacy intervention in terms of reduction in number 
of relapses due to better patient adherence and lower incidence of NAbs compare 
to the other interferons β in the Czech Republic. The one-way sensitivity analyses 
showed that results are the most sensitive to DMD costs and relapse rate.
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